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Low-dose pioglitazone can 
ameliorate learning and memory 
impairment in a mouse model 
of dementia by increasing LRP1 
expression in the hippocampus
Hannah seok1, Minyoung Lee  2, eugene shin3, Mi Ra Yun4, Yong-ho Lee  2, 
Jae Hoon Moon5, eosu Kim6, phil Hyu Lee7, Byung-Wan Lee2, eun seok Kang  2, 
Hyun Chul Lee2 & Bong soo Cha2,3
Amyloid-β (Aβ) accumulation in the brain is a pathological feature of Alzheimer’s disease (AD) and 
enhancing Aβ clearance is a potential therapeutic strategy. pioglitazone is a peroxisome proliferator-
activated receptor-γ (ppAR-γ) agonist and is widely used to treat type 2 diabetes. We previously 
reported that low-dose pioglitazone increased the expression of low-density lipoprotein receptor-
related protein 1 (LRP1), which upregulates the clearance of Aβ, using human brain microvascular 
endothelial cells. We investigated whether low-dose pioglitazone can rescue the pathological 
phenotype and memory impairment in senescence-accelerated mouse prone-8 (SAMP8) mice by 
increasing LRP1 levels. SAMP8 mice were treated with vehicle or pioglitazone in dosages of 2 or 5 mg/
kg/day for 7 weeks. In the water maze test, 2 mg/kg/day of pioglitazone significantly attenuated 
the increased escape latency in SAMP8 mice (p = 0.026), while 5 mg/kg/day of treatment did not. 
Compared with vehicle treatment, the hippocampi of SAMP8 mice with 2 mg/kg/day of pioglitazone 
exhibited fewer Aβ deposits and reduced Aβ1–40 levels, along with elevated LRP1 expression (p = 0.005). 
Collectively, our results proposed that a new therapeutic application of the ppAR-γ agonist for AD 
treatment should be considered at a lower dose than the conventional dose used to treat diabetes.
Alzheimer’s disease (AD) is the most common form of senile dementia in the elderly. Accumulation of amyloid-β 
(Aβ) into the so-called senile plaques, and neurofibrillary tangles are main pathological features of AD1–3. 
Therefore, reducing production of Aβ or increasing the clearance of Aβ from the brain parenchyma could be 
important treatment strategies for AD4–6. A growing body of evidence suggests that the clearance of Aβ is signifi-
cantly impaired in the majority of patients with AD5. Receptor-mediated elimination of Aβ from the brain to the 
periphery is mainly mediated by low-density lipoprotein receptor-related protein 1 (LRP1)7. LRP1, a member of 
the LDL receptor (LDLR) family, binds a diverse array of extracellular ligands, and is abundantly expressed in 
various tissues: the liver, brain, and vessels6,8. LRP1, expressed in the endothelial cells and pericytes of the blood 
brain barrier (BBB), is considered to actively eliminate brain-derived Aβ across the BBB7,9–12, and dysfunction of 
LRP1 significantly exacerbates the accumulation of Aβ in the brain7,13. Additionally, LRP1 in peripheral tissues 
such as the liver can also affect Aβ metabolism in the brain by accelerating the uptake of peripherally circulating 
Aβ14,15. Therefore, several pharmaceutical approaches including statin treatment have been made to enhance 
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LRP1-mediated Aβ clearance in in vitro and in vivo studies16–19. Nevertheless, further studies are desired to eluci-
date the impact of elevated LRP1 on memory improvement in various stages of AD.
Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, is widely used to treat 
hyperglycaemia in type 2 diabetes. This PPAR-γ agonist is a potential candidate to treat AD, as it has been shown 
to improve memory dysfunction and reduce accumulation of Aβ in previous animal studies of AD20–23. However, 
the underlying mechanism remains unknown, and the clinical evidence is controversial24–26. Of note, several 
in vitro studies have reported that pioglitazone increases LRP1 expression in multiple types of cells such as adi-
pocytes, hepatocytes, and microvascular endothelial cells27–29. Interestingly, Moon et al. reported that low-dose 
PPAR-γ agonist treatment, but not the conventional doses, exhibits an Aβ-clearing effect by increasing LRP1 in 
human brain microvascular endothelial cells (HBMECs)29. Another PPAR-γ agonist, rosiglitazone, upregulates 
mRNA and protein levels of LRP1 in addition to LRP1 promoter activity, and increases Aβ uptake via LRP1 in 
HBMECs29. This increase in LRP1 expression and Aβ uptake was observed for concentrations of ≤10 nM of 
PPAR-γ agonist, but not for concentrations ≥20 nM. Considering that a 7-day rosiglitazone oral treatment results 
in concentrations of 260–450 nM in the human brain30, this unusual dose-response in vitro study suggests that a 
new therapeutic application of PPAR-γ agonist for AD should be considered at a lower dose than the conventional 
dose used to treat diabetes. Therefore, it is of great interest to examine whether low-dose pioglitazone can reduce 
Aβ plaque deposition and ameliorate memory impairment in mouse model of AD by increasing LRP1 expression.
In this study, we investigated whether pioglitazone could upregulate LRP1 expression, accompanied by reduc-
tion of Aβ plaque deposition in a mouse model of sporadic AD, senescence-accelerated mouse prone-8 (SAMP8). 
The administered dosages of pioglitazone were 2 or 5 mg/kg/day, comparable with 10 and 26 mg/day by human 
equivalent dose calculation, respectively31,32. Our finding suggests a theoretical basis for the use of pioglitazone in 
treating AD, by demonstrating the efficacy of low-dose pioglitazone in the improvement of memory impairment 
and Aβ pathology-related LRP1 expression in a mouse model of AD.
Results
Low-dose pioglitazone improves spatial learning and memory deficits in aged SAMP8 
mice. In training trials, 11-month-old SAMP8 mice exhibited spatial learning and memory impairment com-
pared with SAMR1 mice in the water maze test (Fig. 1a). The escape latency (time taken to find the hidden 
platform) tended to improve in SAMR1 mice, but not in SAMP8 mice in repeated trials. Notably, 2 mg/kg/day 
of pioglitazone significantly attenuated the escape latency in SMAP8 mice on the 5th day (p = 0.026). The escape 
latency was also decreased by 5 mg/kg/day of pioglitazone compared with vehicle treatment in SAMP8 mice on 
the 5th day, but the difference was not statistically significant (p = 0.274).
In the probe trials, decreased probe latencies and increased searching times were achieved by 2 or 5 mg/kg/day 
of pioglitazone treatment compared with vehicle treatment in SAMP8 mice. However, these improvements were 
not statistically significant (Fig. 1b,c).
Low-dose pioglitazone decreases Aβ plaque depositions and Aβ1–40 levels. Immunohistochemical 
staining for Aβ1–40 revealed significantly increased Aβ deposits in the cortices and hippocampi of vehicle-treated 
SAMP8 mice compared with SAMR1 mice (Fig. 2). The Aβ1–40 deposits were markedly reduced in the hippocampi 
of SAMP8 mice treated with 2 mg/kg/day of pioglitazone compared with vehicle-treated SAMP8 mice (p = 0.013; 
Fig. 2c), but the difference was not apparent in the cortices (Fig. 2b). Compared with vehicle treatment, 5 mg/kg/day 
of pioglitazone treatment did not reduce Aβ1–40 deposits, neither in the hippocampi nor in the cortices of SAMP8 
mice (Fig. 2b,c). Similarly, immunohistochemical staining for Aβ1–42 exhibited that vehicle-treated SAMP8 mice had 
a significantly increased Aβ1–42 deposits in the cortices and hippocampi of vehicle-treated SAMP8 mice compared 
with SAMR1 mice, and 2 mg/kg/day of pioglitazone treatment significantly diminished Aβ1–42 levels compared with 
vehicle treatment in the hippocampi of SAMP8 mice (p = 0.005; Supplementary Fig. S1).
Cortical and hippocampal levels of Aβ1–40 were also determined by enzyme-linked immunosorbent assay 
(ELISA). SAMP8 mice had higher soluble Aβ1–40 levels than SAMR1 mice in both the cortical and hippocampal 
areas, but the difference was only statistically significant in the hippocampi (p = 0.005; Fig. 3a,b). Compared with 
vehicle treatment, treatment of SAMP8 mice with pioglitazone (2 or 5 mg/kg/day) in SAMP8 mice did not signif-
icantly reduce Aβ1–40 levels in cortices (Fig. 3a). SAMP8 mice treated with 2 mg/kg/day of pioglitazone exhibited a 
significantly lower level of Aβ1–40 in the hippocampal area, which is involved in spatial learning and memory, than 
the vehicle-treated SAMP8 mice (p = 0.004; Fig. 3b). A higher dosage of pioglitazone (5 mg/kg/day) did not signifi-
cantly reduce Aβ1–40 levels in the hippocampi of SAMP8 mice, compared with vehicle treatment (p = 0.329; Fig. 3b).
Low-dose pioglitazone increases LRP1 expression in the microvessels of the hippocampal 
area. LRP1 expression in the cortex and hippocampus was evaluated in conjunction with platelet endothelial 
cell adhesion molecule-1 (PECAM-1), an endothelial marker, because LRP1 in the BBB has been demonstrated 
to be an important exporter of Aβ (Fig. 4) Immunofluorescence double staining for LRP1 and PECAM-1 revealed 
that LRP1 was distributed along the blood vessels in the brain (Fig. 4a,b). Quantification of the LRP1 positive area 
revealed that vehicle-treated SAMP8 mice exhibited significantly lowered LRP1 expression than SAMR1 mice in 
both cortical and hippocampal areas (p = 0.001 for both cortical and hippocampal LRP1 levels; Fig. 4c,d). LRP1 
expression in the hippocampus, which modulates brain Aβ clearance, was inversely correlated with hippocam-
pal Aβ levels. LRP1 expression was 1.9-fold increased by 2 mg/kg/day of pioglitazone treatment compared with 
vehicle treatment in the hippocampi of SAMP8 mice (p = 0.005), whereas 5 mg/kg/day of pioglitazone treatment 
showed no significant change on hippocampal LRP1 expression (p = 0.753; Fig. 4d). In the cortical area, the dif-
ference in LRP1 expression was relatively not considerable between vehicle and pioglitazone treatment at either 
dosages (Fig. 4c).
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LRP1 levels were also analyzed in the cortex and hippocampus by western blot (Supplementary Fig. S2). In 
the hippocampal area, the protein levels of LRP1 were decreased in vehicle-treated SAMP8 mice compared with 
SAMR1 mice (p = 0.034). SAMP8 mice treated with 2 mg/kg/day of pioglitazone which exhibited lower hip-
pocampal Aβ1–40 levels, had higher levels of hippocampal LRP1 than vehicle-treated SAMP8 mice (p = 0.050). 
In the cortical area, there were no statistically significant differences in the protein levels of LRP1 between the 
groups (p = 0.776).
Discussion
Compared with SAMR1 mice, SAMP8 mice exhibit significant learning and memory dysfunction between 8 
and 12 months of age due to impairment in neuroprotection, signal transduction, and enhanced Aβ production, 
all of which are processes involved in learning and memory33–36. In this study, we demonstrated that escape 
latency during the water maze test was significantly improved by treatment with 2 mg/kg/day of pioglitazone 
in the SAMP8 mice. Treatment with 2 mg/kg/day of pioglitazone reduced Aβ deposition in SAMP8 mice, and 
significantly increased the hippocampal expression of LRP1, which plays a key role in the clearance of Aβ in the 
brain9–11.
AD is the most common type of dementia and is a debilitating neurodegenerative disease37,38. Nevertheless, no 
effective treatment has yet been developed and AD remains incurable38. Recently, ample evidence has suggested 
that a PPAR-γ agonist could be a potential therapeutic candidate for the treatment of AD39–41. PPARs are nuclear 
receptors that act as ligand-activated transcriptional regulators of genes affecting lipid metabolism20,42. PPAR-γ 
is the most studied isoform of the PPAR family, and controls adipocyte differentiation along with fatty acid and 
glucose metabolism39,43. Regarding the treatment of type 2 diabetes, PPAR-γ agonists decrease plasma fatty acid 
and hyperglycaemia by improving insulin sensitivity39. Pioglitazone is one such PPAR-γ agonist, and has been 
clinically used as an anti-diabetic drug since the 1990s42. In a prospective cohort study of 145,928 subjects with 
type 2 diabetes aged ≥60 years, long-term use of pioglitazone was significantly associated with a lower dementia 
Figure 1. Pioglitazone improves spatial learning and memory in SAMP8 mice. (a) Effect of pioglitazone on 
escape latency in training trial sessions. On the 5th day of the training trial, SAMR1 mice and SAMP8 mice 
treated with 2 mg/kg/day of pioglitazone exhibited significantly decreased escape latency compared with 
vehicle-treated SAMP8 mice. In the probe trial session, (b) probe latency and (c) searching times were not 
significantly improved by treatment with 2 or 5 mg/kg/day of pioglitazone compared with vehicle treatment in 
SAMP8 mice. The data are expressed as the mean ± standard error of the mean (n = 7 for vehicle; n = 5 for each 
dosage of pioglitazone treatment group; and n = 10 for SAMR1 mice). *p < 0.05 compared with  vehicle-treated 
SAMP8 mice.
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incidence with a relative risk of 0.5340. In another prospective randomized trial, 6 months of pioglitazone treat-
ment significantly decreased AD assessment scale and Wechsler memory scale scores in contrast to the control 
group who did not exhibit any improvement41. Several animal studies have also reported the effect of PPAR-γ 
agonists on memory dysfunction in AD mouse models. A previous study reported that pioglitazone treatment 
(9 or 18 mg/kg/day for 9 days) improved spatial memory in a mouse model of scopolamine-induced memory 
impairment44. It has also been reported that rosiglitazone treatment (5 mg/kg/day for 4 weeks) in amyloid pre-
cursor protein (APP) mice improved recognition memory but not spatial memory23. Another study reported that 
chronic treatment with rosiglitazone (30 mg/kg of food for 7 months) rescued the impaired spatial memory45.
Although still largely unknown, PPAR-γ agonists are expected to ameliorate memory impairment in AD 
by several mechanisms. Animal studies have demonstrated that PPAR-γ agonists inhibit neuroinflammation, 
improve mitochondrial function and synapse plasticity, and alleviate tau hyperphosphorylation26,39,46. Regarding 
Aβ accumulation in AD, previous animal studies demonstrated that Aβ production is not affected by treatment 
with a PPAR-γ agonist in the amyloidogenic mouse model23,47. Instead, accumulated evidence suggests that 
PPAR-γ agonists reduce Aβ plaques by enhancing Aβ clearance47–49. In the amyloid precursor protein/presenilin 
1 (APP/PS1) mouse model, treatment with pioglitazone facilitated the clearance of Aβ via overexpression of 
apolipoprotein E (ApoE)47. Additionally, in another study using the APP/PS1 mouse model, the PPAR-γ agonist 
enhanced microglial phagocytosis of Aβ via upregulation of scavenger receptor CD 36 expression49.
However, to the best of our knowledge, none of the previous reports attempted to investigate the mechanism 
underlying PPAR-γ agonist-mediated Aβ clearance in association with LRP1 using an AD mouse model. LRP1 
Figure 2. Immunohistochemistry for Aβ1–40 deposits in the cortices and hippocampi of SAMR1 and SAMP8 
mice. (a) Representative immunohistochemical staining images are shown. The relative area covered by 
Aβ1–40 plaques in (b) cortices and (c) hippocampi of SAMR1 and SAMP8 mice was analyzed. The Aβ1–40 
deposits were increased in the cortices and hippocampi of SAMP8 mice compared with SAMR1 mice. The 
Aβ1–40 deposits were reduced in the hippocampi of SAMP8 mice treated with 2 mg/kg/day of pioglitazone 
compared with vehicle-treated SAMP8 mice, but the difference was not significant in the cortices. Values are 
the mean ± standard error of the mean (n = 8 per each group). *p < 0.05 compared with SAMR1 mice. #p < 0.05 
compared with vehicle-treated SAMP8 mice. ∮p < 0.05 compared with SAMP8 mice treated with 2 mg/kg/day 
of pioglitazone. The scale bar represents 100 μm.
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has received considerable attention as a therapeutic target of AD, as preclinical studies indicated that LRP1 largely 
contributes to the pathogenesis of AD by modulating Aβ clearance as well as via an Aβ-independent mecha-
nism6,7. Although previous reports have evaluated the effect of pioglitazone on LRP1 expression in the brain 
using animal models, those mouse models had metabolic features of diabetes; thus, it was difficult to exclude the 
anti-diabetic effect of pioglitazone from the results50,51. Our study is the first to investigate whether LRP1 level 
is associated with improved memory impairment using the PPAR-γ agonist, pioglitazone, in the SAMP8 mouse 
model. In our study, a reduction of Aβ burden was observed after pioglitazone treatment, and immunofluores-
cence staining of LRP1 merged with the endothelial marker, PECAM-1, revealed increased LRP1 expression in 
pioglitazone-treated SAMP8 mice. SAMP8 mice treated with 2 mg/kg/day of pioglitazone exhibited the great-
est reduction in Aβ levels along with the greatest increase in LRP1 levels in the hippocampus, suggesting that 
elevated LRP1 was closely related to reduction of Aβ. Furthermore, improvements in the water maze test were 
only observed in the group treated with 2 mg/kg/day of pioglitazone. This result also supported the notion that 
increased LRP1 with reduction of Aβ in the hippocampus could be responsible for the learning and memory 
improvement promoted by pioglitazone treatment.
Despite considerable experimental evidence from in vitro and in vivo models, the efficacy of PPAR-γ agonists 
in AD treatment remains controversial24–26,37,52. In a meta-analysis encompassing nine clinical studies of 1,314 
patients and 1,311 control subjects, statistical evidence was insufficient to support the effect of a PPAR-γ agonist 
on memory improvement in patients with AD and mild-to-moderate AD37. In a previous 18-month randomized 
controlled trial of pioglitazone, no treatment effects were observed on the efficacy outcomes (measures of cog-
nition, activities of daily living, neuropsychiatric symptoms, and global function)24. Of note, in the majority of 
previous clinical studies, the PPAR-γ agonist was applied at conventional doses used to treat type 2 diabetes or 
even higher24,25,37,52,53. A previous animal study using Wistar rats reported that the functional connectivity with 
the CA1 region of the hippocampus, a region responsible for memory that is impaired in early AD, was signifi-
cantly increased by pioglitazone treatment at 0.08 mg/kg/day54. The smallest increase in functional connectivity 
with the CA1 region was observed at the highest pioglitazone dose54, suggesting a better therapeutic potential of 
lower dose pioglitazone compared with higher doses. Furthermore, recent in vitro studies have shown that rosigl-
itazone increases LRP1 expression and Aβ uptake in microvascular endothelial cells at concentrations approx-
imately 10- to 20-fold lower than clinically-used doses29. Similar to the previous results of in vitro studies, we 
administered pioglitazone at doses approximately 10- to 20-fold lower than the generally used doses of 20–40 mg/
kg/day in other previous animal studies20,26,55. Our study proved that 2 mg/kg/day of pioglitazone had an effect 
on Aβ accumulation and LRP1 expression, with significant learning and memory improvement in an AD mouse 
model. This unusual dose administration awards our data a novelty status. Current findings support that low-dose 
pioglitazone should be considered in the attempt to find a new therapeutic application of PPAR-γ agonists in AD. 
PPAR-γ agonists have pleiotropic physiological functions, and are expected to play a beneficial role in treating 
AD by regulating multiple aspects in the pathogenesis of AD26. Conventional and higher doses of pioglitazone 
may have beneficial effects on AD. The possibility of pioglitazone’s beneficial effects on AD in various dosages and 
via mechanisms other than the one involving LRP1 still exists. However, we focused on that low-dose pioglita-
zone could positively impact on the LRP1 molecular pathway during the development of AD in this study. Since 
previous clinical studies of pioglitazone at conventional doses yielded conflicting results, future studies should 
consider a lower dose targeting an increase of LRP1 levels.
Figure 3. Effect of pioglitazone on the levels of Aβ1–40 in brain regions of SAMR1 and SAMP8 mice. (a) 
Cortical and (b) hippocampal relative levels of Aβ1–40 were determined by ELISA. SAMR1 mice were used as 
the reference group. Values are the mean ± standard error of the mean (n = 4–5 for cortical Aβ1–40 levels per 
group; and n = 5–8 for hippocampal Aβ1–40 levels per group). *p < 0.05 compared with SAMR1 mice. #p < 0.05 
compared with vehicle-treated SAMP8 mice.
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Figure 4. Immunofluorescence staining for LRP1 and PECAM-1 in (a) the cortex and (b) the hippocampus. 
LRP1 (green) expression was merged with that of PECAM-1 (red). The relative LRP1 positive area was 
quantified in (c) cortices and (d) hippocampi of SAMR1 and SAMP8 mice. Compared with SAMR1 mice, 
SAMP8 mice exhibited decreased LRP1 expression in the cortex and hippocampus. Decreased LRP1 expression 
in the hippocampi of vehicle-treated SAMP8 mice was significantly improved by 2 mg/kg/day of pioglitazone 
treatment. Values are the mean ± standard error of the mean (n = 8 per group). *p < 0.05 compared with 
SAMR1 mice. #p < 0.05 compared with vehicle-treated SAMP8 mice. ∮p < 0.05 compared to SAMP8 mice 
treated with 2 mg/kg/day of pioglitazone. The scale bar represents 50 μm.
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This study is not without limitations. First, unfortunately, the LRP1 levels in the microvasculature and paren-
chyma tissues were not quantified separately in this study. A recent study reported that LRP1 expression is pre-
dominant in neurons but is down-regulated in the brain microvasculature in AD56. These results also suggested 
that the role of LRP1 expression might differ between the microvasculature and the parenchyma. Thus, follow-up 
studies should be performed to clarify the role of LRP1 in AD in addition to the effects on LRP1 expression in 
microvessels and other areas of the brain. Second, a motor activity test such as the rotarod test was not performed 
to confirm any motoric disabilities that could have affected the swimming, although learning in the water maze 
test basically relies on motor performance57,58. Third, we could not demonstrate any improvement by pioglitazone 
treatment in the probe trials to assess retention memory. This unimproved retention memory could be caused by 
the ceiling effect of aging, and further study using mice of different ages needs to be conducted.
Collectively, our data demonstrated that low-dose pioglitazone ameliorates AD pathology and restores spatial 
learning and memory impairment in SAMP8 mice. As we hypothesized, pioglitazone possibly facilitated the 
clearance of Aβ, via activation of LRP1 in the hippocampus. Considering that no effective drug has been devel-
oped to treat AD, our study proposed the novel therapeutic potential of PPAR-γ agonist for AD treatment at a 
lower dose than the conventional clinical dose to treat diabetes.
Methods
Animals and drug treatments. SAMP8 mice representing the behavioural and pathological features of 
late-onset and age-related sporadic AD were used in this study59,60. Considering the life span and age-related 
memory impairment of SAMP8 mice34,60–63, 9-month-old male SAMP8 mice were purchased from Japan SLC, 
Inc., Shizuoka, Japan. Animals were housed individually with food and water ad libitum and maintained under 
controlled conditions (12 h light/dark cycle; 25 ± 2 °C). Age-matched senescence-accelerated-resistant mice 1 
(SAMR1) were used as a normal aging control and treated with vehicle by oral gavage for 7 weeks (n = 10). 
SAMP8 mice were treated with vehicle or pioglitazone hydrochloride (AD-4833, Takeda Pharmaceuticals, 
Kanagawa, Japan) as a suspension in sterile water by oral gavage at dosages of 2 or 5 mg/kg/day for 7 weeks 
(n = 7 for vehicle; and n = 5 for each dosages of pioglitazone). In all cases, animals were euthanized 24 h after 
the final administration. The brains were then removed and immediately frozen on dry ice before dissection. All 
animal experiments in this study were approved by the Institutional Animal Care and Use Committee of Yonsei 
University Health System (YUHS-IACUC). The YUHS-IACUC has regulations, notifications, and guidelines that 
are in accordance with the Animal Protection Act (2008), the Laboratory Animal Act (2008), and the Eighth 
Edition of the Guide for the Care and Use of Laboratory Animals of NRC (2011). Thus, all animal experiments 
in this study have been performed in accordance with the guidelines and regulations of the YUHS-IACUC as 
described above.
Cortex and hippocampus slice preparation and immunohistochemistry. Brain tissues from mice 
were fixed in 10% formaldehyde and embedded in paraffin. The paraffin sections were cut and deparaffinized 
using xylene and ethanol. After inactivation of endogenous peroxidase with 3% H2O2 for 10 min at 22 ± 2 °C, 
samples were blocked with 5% bovine serum albumin (BSA) for 1 h. The tissues were then incubated overnight 
with a mouse anti-amyloid β1–40 antibody (1:100, AnaSpec Inc, Fremont, CA, USA) or a mouse anti-amyloid 
β1–42 antibody (1:100, AnaSpec Inc, Fremont, CA, USA) at 4 °C. After washing, tissues were incubated with an 
appropriate secondary antibody (horseradish peroxidase-labelled coat anti-mouse IgG, 1:1000; ZSJQ) for 1 h 
at room temperature. Staining for mouse primary antibodies was performed using an EnVision + System-HRP 
Labelled Polymer Anti-Mouse kit (K4001, Dako, Glostrup, Denmark). Coverslips were washed and incubated 
with 3,3′-diaminobenzidine (DAB; K3468, Dako) for 5 min and counterstained with haematoxylin prior to exam-
ination under a light microscope (Olympus BX40, Olympus Optical Co. Ltd., Tokyo, Japan). Images of immu-
nohistochemically stained sections were captured using an Olympus DP71 microscope digital camera and the 
relative levels Aβ1–40 and Aβ1–42 were quantified using Image J software. After adjusting for the threshold within 
the section image, the percent surface area above the threshold was then measured to determine the total area of 
the Aβ plaques and the percentage of the total brain area occupied by the Aβ plaques. Data pooled from 4 slide 
sections at ×400 magnification per each mouse were used for statistical analysis.
Immunofluorescence. Brain tissues from mice were fixed in 10% formaldehyde and embedded in paraffin. 
The paraffin sections were cut and deparaffinised using xylene and ethanol. Deparaffinised sections were under-
went antigen retrieval in Proteinase K (Proteolytic enzyme solution diluted in 0.05 M Tris-HCl, 15 mM sodium 
azide, pH 7.5) at room temperature for 10 min. The brain sections were then washed and blocked for 1 h at room 
temperature with 5% BSA. The slides were then incubated with a rabbit anti-LRP1 antibody (ab199567; 1:200, 
Abcam®, Cambridge, MA, USA) and a mouse anti-PECAM-1 antibody (ab24590; 1:200, Abcam®, Cambridge, 
MA, USA) overnight at 4 °C. After three 5-min washes in Tris-buffered saline (TBS), the slides were incubated 
with an Alexa 488-conjugated chicken anti-rabbit IgG antibody (A21441; 1:500, Invitrogen, Carlsbad, CA, USA) 
and an Alexa 647-conjugated goat anti-mouse IgG antibody (ab150115; 1:500, Abcam®, Cambridge, MA, USA) 
in blocking buffer for 30 min at 22 ± 2 °C. The sections were then washed and mounted on coverslip with fluo-
rescent mounting media (Dako). Fluorescence images were examined using a Zeiss Laser Scanning Confocal 
Microscope (LSM 700, Carl Zeiss, Oberkochen, Germany) and the Zen 2012 software (Zeiss) was used for image 
processing. All images were acquired using identical acquisition parameters as 24-bit, 1024 × 1024 arrays. The 
relative levels of immunofluorescence staining for LRP1 were quantified using Image J software. After adjusting 
for the threshold to isolate specific fluorescence within the section image, the percent surface area above the 
threshold was then measured to determine the relative LRP1 positive area. Data pooled from 4 slide sections 
at × 400 magnification per each mouse were used for the statistical analysis.
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ELISA measurement of Aβ1–40. Soluble Aβ1–40 levels in the cortex and hippocampus were measured with 
a sensitive sandwich ELISA kit (Catalogue # KMB3481, Thermo Scientific, Rockford, IL, USA). Briefly, the tis-
sue was weighed and homogenized in 100 μl of phosphate-buffered saline (PBS) followed by centrifugation at 
16,000× g for 10 min at 4 °C. The supernatant was diluted with standard diluent buffer supplemented with Halt® 
protease inhibitor cocktail (Thermo Scientific, Rockford, IL, USA). A total of 600 pg/ml was loaded onto ELISA 
plates in duplicate, and the manufacturer’s instructions were followed.
Western blot analysis. Proteins were extracted from the homogenized frozen brain tissue using TPER® 
(Thermo Scientific) mixed with Halt® protease inhibitor cocktail (Thermo Scientific). Protein concentrations 
were determined using a BCA Protein Assay kit (Thermo Scientific) and appropriate amounts of protein were 
mixed with sodium dodecyl sulphate (SDS) sample buffer [62.5 mM Tris-HCl pH 6.8, 25% (v/v) glycerol, 2% 
SDS (w/v), 0.01% (w/v) bromophenol blue, 5% (v/v) β-mercaptoethanol]. Lysates (20 μg per sample) were sep-
arated by 10% (w/v) SDS-polyacrylamide gel electrophoresis (PAGE), and the resolved proteins were trans-
ferred onto nitrocellulose membranes (GE Healthcare Life Sciences, Pittsburgh, PA, USA). Blots were blocked 
with 5% w/v non-fat milk in TBST (TBS containing 0.1% v/v Tween 20) for 1 h and incubated with a rabbit 
anti-LRP1 antibody (1:50,000, Abcam®, Cambridge, MA, USA) overnight at 4 °C. After incubation with horse-
radish peroxidase-conjugated goat anti-rabbit IgG (1:10,000, Thermo Scientific) for 1 h at 22 ± 2 °C, signals were 
detected using SuperSignal® West Pico Chemiluminescent Substrate reagent (Thermo Scientific). Images were 
captured and analyzed with a LAS-4000 luminescent image analyzer (Fujifilm Life Science, Stamford, CT, USA)
Morris water maze. Animals underwent spatial reference learning using the Morris water maze test after 7 
weeks of vehicle or pioglitazone treatment with minor modifications from the previously reported methods44,64,65. 
The Morris water maze consists of a large circular pool (90 cm in diameter, 45 cm in height), filled to a depth of 
30 cm with water at 20 ± 3 °C. The water was made opaque with a non-toxic black coloured dye. The pool was 
divided arbitrarily into four equal quadrants. A submerged platform was centred in one of the target quadrants 
of the pool and submerged 1 cm below the water surface. The position of the platform was unaltered throughout 
the training trial sessions. Basic training was composed of a hidden-platform acquisition training session and a 
probe trial session.
The training trials were performed twice daily for 5 consecutive days. At the start of each training trial, mouse 
was placed on the platform for 15 s and then randomly placed in the water pool. Each trial was terminated when 
the mouse reached the platform or after 60 s, whichever occurred first. The time taken to find the hidden plat-
form (escape latency) was recorded in each trial. After completing the final training trial session, the mice were 
subjected to a probe-trial session in which the platform was removed from the pool. Probe-trials were performed 
with a cut-off time of 60 s and determined whether mice could find the previous platform site. Probe latency (the 
initial time that the mice crossed the former platform) and searching times (the number of times that the mice 
crossed the former platform) were monitored by a camera mounted in the ceiling directly above the pool, and all 
trials were recorded using a water maze program.
statistical analysis. Data are expressed as the mean ± standard error of the mean. For animal experiments, 
data collection and analysis were performed blinded to the condition of the experiments. Statistical significance 
was confirmed using the Mann Whitney U-test when comparing two groups or the Kruskal-Wallis test when 
comparing more groups. P-values of < 0.05 were considered as statistically significant. All statistical analyses were 
conducted using SPSS software, version 23.0, for Windows (IBM Corp., Armonk, NY, USA).
Data Availability
All data generated or analyzed during this study are included in this published article.
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